Recent developments for Prenetics include earnings call disclosures for Q1 and Q2 2026, expansion of the IM8 brand through a partnership with Lily Collins, appointment of a new US CFO for IM8, leadership share purchases, and authorization of a share repurchase program.

• Prenetics held Q2 2026 earnings calls with detailed transcripts and highlights publicly available [N1][N3].
• The company expanded the global reach of its IM8 brand through a partnership with actress Lily Collins in August 2026 [N2].
• Prenetics appointed Brian Rosin as US CFO of IM8 in May 2026 [N7].
• The Board authorized a share repurchase program in March 2026 [N8].
• Members of Prenetics' leadership team made open market purchases of shares as announced in August 2026 [S2].

Prenetics has demonstrated the ability to scale health-related services rapidly, as evidenced by its COVID-19 testing volume and revenue during the pandemic. The company’s focus on longevity and wellness through the IM8 brand, supported by medical expertise and celebrity partnerships, positions it to capitalize on growing consumer interest in health optimization. Recent leadership appointments and share repurchase programs indicate active management engagement and capital allocation discipline. The company’s strong liquidity ratios provide financial flexibility to support growth initiatives.

Prenetics reported a significant net loss in fiscal 2024, indicating ongoing challenges in achieving profitability. The company operates in a competitive and evolving health and wellness market, where consumer preferences and regulatory environments may shift. The reliance on key leadership and partnerships introduces execution risk. The valuation of intangible assets and goodwill involves significant judgment and could lead to impairment charges. Market conditions and operational execution will influence the company’s ability to sustain growth and improve financial performance.

Prenetics' moat is anchored in its integrated health and longevity brand IM8, which benefits from co-founding by high-profile figures such as David Beckham and the involvement of medical experts like Dr. Darshan Shah. The company's experience in large-scale COVID-19 testing and established public listing provide operational scale and market access. Its share incentive plans and leadership team with deep expertise in healthcare, finance, and consumer brands support sustained innovation and execution. The company's liquidity position and strategic partnerships contribute to its competitive positioning in the health and wellness sector.

• Profitability Risk: The company reported a net loss of $49.81 million in 2024, reflecting challenges in achieving profitability and potential ongoing operating losses.
• Market and Competitive Risk: Prenetics operates in a competitive health and wellness sector with evolving consumer preferences and regulatory requirements that may impact business performance.
• Execution Risk: The company’s growth depends on successful execution of its global expansion, partnerships, and product development, which may be affected by leadership changes or operational challenges.
• Valuation and Impairment Risk: Significant judgment is involved in valuing intangible assets and goodwill, with potential for future impairment charges if assumptions about future cash flows or market conditions change.

• Prenetics Global Ltd is a company with a flagship health and longevity brand called IM8, co-founded with David Beckham and wholly owned by Prenetics [S1].
• The company performed 28 million COVID-19 tests and generated approximately $700 million in revenue during the pandemic [S1].
• Prenetics completed a public listing on the Nasdaq Stock Exchange [S1].
• The company’s leadership includes CEO and Chairman Danny Sheng Wu Yeung, independent directors Cheng Yin Pan (Ben) and Dr. Darshan Shah, director and President of Americas David Eric Vanderveen, and CFO Lo Hoi Chun (Stephen) [S1].
• Dr. Darshan Shah is a board-certified surgeon and expert in longevity medicine, providing technical oversight as Prenetics scales its science-backed product ecosystem including IM8 [S1].
• Prenetics has a 2021 Share Incentive Plan and a 2022 Share Incentive Plan allowing issuance of shares and awards to employees, directors, and consultants [S1].
• The company’s consolidated financial statements are prepared under IFRS and include significant estimates and judgments, especially regarding impairment testing of goodwill and intangible assets [S1].
• Prenetics reported cash and cash equivalents of $52.25 million as of December 31, 2024, current assets of $86.15 million, and current liabilities of $36.55 million, resulting in a current ratio of 2.36 and a cash ratio of 1.43 [S1].
• The company reported a net loss of $49.81 million for the fiscal year ended December 31, 2024, and basic and diluted EPS of -$3.71 per share [S1].
• Prenetics leadership team members made open market purchases of shares as announced in August 2026 [S2].
• Prenetics expanded the global reach of its IM8 brand through a partnership with actress Lily Collins in August 2026 [N2].
• The company held earnings calls for Q1 and Q2 2026 with detailed highlights and transcripts publicly available [N1, N3, N5, N6].
• Prenetics appointed Brian Rosin as US CFO of IM8 in May 2026 [N7].
• The Board authorized a share repurchase program in March 2026 [N8].